BG
VYNT

Bahl & Gaynor’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Bahl & Gaynor’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-133
Closed -$2K – 365
2019
Q3 		$2K Hold
133
– – ﹤0.01% 350
2019
Q2 		$3K Hold
133
– – ﹤0.01% 352
2019
Q1 		$5K Buy
133
+66
+99% +$2.71K ﹤0.01% 345
2018
Q4 		$2K Buy
+67
New +$5.65K ﹤0.01% 337

Other funds holding VYNT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
LI
Leap Investments Chicago, Illinois $152M AUM 3.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bahl & Gaynor's VYNT Position: Q4 2019 in Review

Bahl & Gaynor sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2019, closing a stake of 133 shares — an estimated $2K sold.

Bahl & Gaynor first reported a position in VYNT in Q4 2018 and held it in 4 quarters. The position peaked at $5K in Q1 2019. 18 funds tracked by Wall St. Rank hold VYNT as of Q4 2019.

  • Bahl & Gaynor reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Bahl & Gaynor sold 133 Vyant Bio, Inc. Common Stock shares in Q4 2019, an estimated $2K.
  • Bahl & Gaynor first reported a position in Vyant Bio, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
  • Bahl & Gaynor's Vyant Bio, Inc. Common Stock position peaked at $5K in Q1 2019.
  • 18 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2019.

Based on Bahl & Gaynor's 13F filing for Q4 2019, filed 14 Feb 2020.